)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Immunic
Immunic (IMUX) investor relations material
Immunic Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary30 Apr, 2026
Company overview and business model
Late-stage biotechnology company developing novel oral therapies for neurologic and gastrointestinal diseases, with headquarters in New York and main operations in Germany.
Lead candidate vidofludimus calcium (IMU-838) is in Phase 3 trials for relapsing multiple sclerosis, with additional programs in gastrointestinal and autoimmune diseases.
Pipeline includes IMU-856 for gastrointestinal disorders and IMU-381 leveraging the Nurr1 platform for neuroinflammatory and autoimmune diseases.
Employs 92 staff as of February 2026, with R&D activities centered in Germany and Australia.
Financial performance and metrics
February 2026 private placement raised approximately $200 million in gross proceeds through the sale of pre-funded and common warrants.
Aggregate exercise price of the common warrants is approximately $200 million.
Use of proceeds and capital allocation
Will not receive proceeds from resale of shares by selling stockholders; proceeds from warrant exercises, if any, will be used for working capital and general corporate purposes.
All registration costs are borne by the company; selling stockholders pay their own brokerage fees and commissions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Immunic
- Biotech registers 67% of shares for resale after $200M raise; key MS trial data due 2026.IMUX
Registration filing2 Apr 2026 - Phase III RMS data and NDA prep position a novel, safer MS therapy for major market impact.IMUXStifel 2026 Virtual CNS Forum18 Mar 2026
- Phase III MS trials for a novel dual-mechanism therapy near readout, targeting major market segments.IMUXLeerink Global Healthcare Conference 202611 Mar 2026
- Vote on a reverse stock split to maintain Nasdaq listing and support capital access.IMUXProxy Filing2 Mar 2026
- $200M raised to fund phase 3 MS trials and commercial transition, with data expected by end 2026.IMUXQ4 202526 Feb 2026
- Shareholders will vote on a reverse stock split to maintain Nasdaq listing and support liquidity.IMUXProxy Filing20 Feb 2026
- Q2 net loss narrowed, cash at $79.7M, but liquidity concerns persist as trials advance.IMUXQ2 20242 Feb 2026
- Oral MS therapy shows dual neuroprotection and strong efficacy, with major trials underway.IMUX2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026
- Q3 net loss was $24.4M; MS trials advanced, but liquidity concerns persist.IMUXQ3 202416 Jan 2026
Next Immunic earnings date
Q1 202621 May, 2026
Immunic
Next Immunic earnings date
Q1 202621 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage